Log in
CNSX:CURE

Direxion Daily Healthcare Bull 3X Shares Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume44,500 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab. The company is developing Interferons- Ã for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing CAR T Cell Therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and a hair growth production product. Biocure Technology Inc. is headquartered in Vancouver, Canada.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-609-7149
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive CURE News and Ratings via Email

Sign-up to receive the latest news and ratings for CURE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Direxion Daily Healthcare Bull 3X Shares (CNSX:CURE) Frequently Asked Questions

What stocks does MarketBeat like better than Direxion Daily Healthcare Bull 3X Shares?

Wall Street analysts have given Direxion Daily Healthcare Bull 3X Shares a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Direxion Daily Healthcare Bull 3X Shares wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Direxion Daily Healthcare Bull 3X Shares' key competitors?

What other stocks do shareholders of Direxion Daily Healthcare Bull 3X Shares own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Direxion Daily Healthcare Bull 3X Shares investors own include NVIDIA (nvda), Advanced Micro Devices (AMD), Gilead Sciences (gild), Merck & Co., Inc. (MRK), Micron Technology (MU), Spotify Technology (SPOT), Square (SQ), Tesla (TSLA), Abbott Laboratories (ABT) and AbbVie (ABBV).

Who are Direxion Daily Healthcare Bull 3X Shares' key executives?

Direxion Daily Healthcare Bull 3X Shares' management team includes the following people:
  • Dr. Sang Mok Lee Ph.D., Pres, CEO & Director (Age 54, Pay $101.38k)
  • Mr. Konstantin Lichtenwald CPA, CGA, CFO, Corp. Sec. & Director (Age 36, Pay $50k)
  • Mr. Marco Nonni, Consultant

What is Direxion Daily Healthcare Bull 3X Shares' stock symbol?

Direxion Daily Healthcare Bull 3X Shares trades on the CNSX under the ticker symbol "CURE."

How do I buy shares of Direxion Daily Healthcare Bull 3X Shares?

Shares of CURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Direxion Daily Healthcare Bull 3X Shares' official website?

The official website for Direxion Daily Healthcare Bull 3X Shares is www.biocuretech.com.

How can I contact Direxion Daily Healthcare Bull 3X Shares?

The company can be reached via phone at 604-609-7149.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.